Intravenous infusion of umbilical cord blood mononuclear cells in patients with ischemic stroke

Abstract

Objective To study the effect of multiple human umbilical cord blood mononuclear cells (HCMNC) on the neurological and motor function as well as living activities in patients with ischemic stroke via intravenous transplantation. Methods According with the Fourth National Conference on cerebrovascular disease, 76 cases of ischemic stroke patients confirmed by CT and MRI, and in the second people's Hospital of Zhengzhou, Zhengzhou bridge hospital and outpatient from April 2008 to May 2015 were collected and divided into treatment group and controls according to the clinical trial protocol. The control groups in the acute and chronic stage were treated routinely and treated with rehabilitation therapy, respectively. On the basis of conventional therapy or rehabilitation therapy, the treatment group was treated with HCMNC of umbilical cord blood which were intravenously infused into the superficial vein of the back of the hand. Each patient received averagely 6 copies (cell number over 1×108/each), each time interval lasted 1 to 7 days, average 4 days. The comparison for the difference of the NFD, FMA and ADL before and after therapy was performed using pared t test and the comparison between groups was made using independent-samples t test. Results In acute stage, the NFD scores in HCMNC group after treatment with HCMNC (12.41±3.83) were significantly lower than those in before treatment group (26.83±5.55, t = 6.186, P < 0.01) and control group (24.33±5.16, t = 5.442, P < 0.01); In restoration stage, the NFD scores in HCMNC group after treatment with HCMNC (12.41±3.83) were significantly lower than those in before treatment group (23.1±4.54, t = 10.184, P < 0.01) and control group (23.09 ± 3.94, t = 11.012, P < 0.01); In acute stage, Fuel-Meyer in HCMNC group after treatment with HCMNC (upper limbs 22.16±2.63, lower limbs 32±5.32) were significantly lower than those in before treatment group (upper limbs 11.66±2.94, t = -6.505, P < 0.01; lower limbs 12.66±3.01, t = -7.5386, P < 0.01) and control group (upper limbs 15±3.63, t = -3.871, P = 0.003; lower limbs 16.83±4.91, t = -5.048, P < 0.01), In restoration stage, Fuel-Meyer in HCMNC group after treatment with HCMNC (upper limbs 15.10±2.08, lower limbs 15.03±1.86) were significantly lower than those in before treatment group (upper limbs 8.81±2.19, t = -11.748, P < 0.01; lower limbs 8.84±2.30, t = -12.619, P < 0.01) and control group (upper limbs 9.16±2.60, t = -10.069, P < 0.01; lower limbs 9.69±2.98, t = -11.441, P < 0.01); In acute stage, Barthel index scores in HCMNC group after treatment with HCMNC (12.41±3.83) were significantly lower than those in before treatment group (21.66±5.57, t = -11.916, P < 0.01) and control group (42.5±5.2, t = -6.387, P < 0.01); In restoration stage, Barthel index scores in HCMNC group after treatment with HCMNC (63.4±9.19) were significantly lower than those in before treatment group (25.2±3.81, t = -21.733, P < 0.01) and control group (29.9±5.36, t = 20.361, P < 0.01). Conclusion The intravenous transplantation of multiple human umbilical cord blood mononuclear cells has been proved a suitable method for the treatment of ischemic stroke with advantages of simpleness, safety and effectivity. Key words: Umbilical cord blood mononuclear cells; Intravenous infusion; Ischemic stroke